Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Prevalence of non-organ specific autoantibodies detected by indirect immunofluorescence (IIFL) or enzyme linked immunosorbent assay (ELISA) in patients with chronic hepatitis C and B.

From: Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis

  Anti-LKM1 (IIFL) Anti-LC1 (ELISA) Anti-SLA (ELISA) ANA (IIFL) SMA (IIFL)
LKM1pos/HCVpos 18/18 (100%)* 6/18 (33%) 0/18 (0%) 5/18 (27.7%)** 6/18 (33%)***
LKM1neg/HCVpos 0/120 (0%) 1/120 (0.8%) 0/120 (0%) 45/120 (37.5%)** 61/120 (50.8%)***
LKM1neg/HBVpos 0/120 (0%) 0/120 (0%) 0/120 (0%) 23/120 (19.2%)** 15/120 (12.5%)***
  1. LKM1, liver kidney microsomal type 1; LC1, liver cytosol type 1; SLA, soluble liver antigen; ANA, anti-nuclear antibody; SMA, smooth muscle antibody; pos, positive; neg, negative; *Confirmed by Western immunoblotting (see Methods section); **Low titers of ANA were detected in the three groups (mean titer: 1/168, 1/148 and 1/140, respectively); ***Low titers of SMA were detected in the three groups (mean titer: 1/134, 1/121 and 1/119, respectively).